Fluctuations in quality of life and immune responses during intravenous immunoglobulin infusion cycles

Despite adequate infection prophylaxis, variation in self-reported quality of life (QOL) throughout the intravenous immunoglobulin (IVIG) infusion cycle is a widely reported but infrequently studied phenomenon. To better understand this phenomenon, subjects with humoral immunodeficiency receiving re...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2022-03, Vol.17 (3), p.e0265852-e0265852
Main Authors: Abbott, Jordan K, Chan, Sanny K, MacBeth, Morgan, Crooks, James L, Hancock, Cathy, Knight, Vijaya, Gelfand, Erwin W
Format: Article
Language:English
Subjects:
Analysis
Biology and Life Sciences
Blood
Carbon tetrachloride
CCL3 protein
CCL4 protein
Chemokines
Cytokines
Cytokines - metabolism
Enrollments
Fluctuations
Granulocyte-macrophage colony-stimulating factor
Granzyme B
Growth factors
Humans
Immune response
Immune system
Immunity
Immunodeficiency
Immunoglobulins
Immunoglobulins, Intravenous - pharmacology
Immunoglobulins, Intravenous - therapeutic use
Immunology
Inflammation
Interferon
Interleukin 1 receptor antagonist
Interleukin 1 receptors
Interleukin 10
Interleukin 6
Interleukin 8
Intravenous administration
Lymphocytes T
Macrophage inflammatory protein
Macrophage inflammatory protein 1
Medical diagnosis
Medicine
Medicine and Health Sciences
Monocyte chemoattractant protein 1
Monocytes
Patients
Pediatrics
Prophylaxis
Quality of Life
Questionnaires
Tumor Necrosis Factor-alpha - metabolism
Well being
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite adequate infection prophylaxis, variation in self-reported quality of life (QOL) throughout the intravenous immunoglobulin (IVIG) infusion cycle is a widely reported but infrequently studied phenomenon. To better understand this phenomenon, subjects with humoral immunodeficiency receiving replacement doses of IVIG were studied over 3 infusion cycles. Questionnaire data from 6 time points spread over 3 IVIG infusions cycles (infusion day and 7 days after each infusion) were collected in conjunction with monitoring the blood for number of regulatory T-cells (Treg) and levels of 40 secreted analytes: primarily cytokines, chemokines, and growth factors. At day 7, self-reported well-being increased, and self-reported fatigue decreased, reflecting an overall improvement in QOL 7 days after infusion. Over the same period, percentage of Treg cells in the blood increased (p
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0265852